In May 2019 the Advanced Therapies Network (ATN) held its second event on investment. Amongst the panellists was Simon Goldman from UCL Technology Fund.
Held at the Silicon Valley Bank in Moorgate London, the second ATN event was entitled ‘Recipe for an Advanced Therapies Unicorn: Investment Journey’ and brought together speakers and panellists to consider the unique nature of the relationship between investor and company in the cell and gene therapy sector. It featured speakers from Autolus and LIfT Biosciences talking about their investment journey and a panel of investors who discussed what they are looking for in an advanced therapies company and their way of working.
Simon Goldman, Investment Director at UCL Technology Fund, was one of the panellists at the event. ATN media partners RegMedNet interviewed him before the ATN Investment event to get his views on translational potential, scalability and patient access.